Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) insider Gregory Russotti sold 5,000 shares of the company's stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $3.10, for a total value of $15,500.00. Following the completion of the transaction, the insider now owns 297,319 shares in the company, valued at $921,688.90. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Century Therapeutics Price Performance
IPSC stock opened at $2.96 on Thursday. Century Therapeutics, Inc. has a one year low of $1.28 and a one year high of $5.51. The company's 50 day moving average price is $4.10 and its two-hundred day moving average price is $3.13.
Century Therapeutics (NASDAQ:IPSC - Get Free Report) last issued its earnings results on Thursday, March 14th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.07. The company had revenue of $0.27 million for the quarter, compared to analysts' expectations of $1.69 million. Century Therapeutics had a negative net margin of 6,115.12% and a negative return on equity of 54.73%. As a group, analysts anticipate that Century Therapeutics, Inc. will post -1.94 earnings per share for the current year.
Institutional Investors Weigh In On Century Therapeutics
FW: 234x Gain
From Weiss Ratings | Ad
This coin is an essential building block for an ongoing financial revolution of massive dimensions.
As a big part of this revolution, the big banks of the world must connect to the blockchain.
Click here.
A number of hedge funds and other institutional investors have recently modified their holdings of IPSC. Federated Hermes Inc. increased its stake in Century Therapeutics by 0.4% in the 4th quarter. Federated Hermes Inc. now owns 618,482 shares of the company's stock worth $2,053,000 after purchasing an additional 2,500 shares during the period. Abel Hall LLC bought a new position in shares of Century Therapeutics in the fourth quarter worth approximately $33,000. Finally, Avidity Partners Management LP increased its stake in shares of Century Therapeutics by 23.4% in the fourth quarter. Avidity Partners Management LP now owns 1,355,000 shares of the company's stock worth $4,499,000 after buying an additional 256,500 shares during the period. Institutional investors own 50.20% of the company's stock.
Analyst Ratings Changes
Several research firms recently weighed in on IPSC. Piper Sandler restated an "overweight" rating and issued a $9.00 price objective (down from $10.00) on shares of Century Therapeutics in a research report on Friday, April 12th. Canaccord Genuity Group increased their price target on shares of Century Therapeutics from $22.00 to $24.00 and gave the stock a "buy" rating in a report on Friday, March 15th. Finally, HC Wainwright restated a "buy" rating and set a $13.00 price objective on shares of Century Therapeutics in a research report on Friday, March 15th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Century Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $13.60.
Get Our Latest Analysis on IPSC
About Century Therapeutics
(
Get Free Report)
Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
